Compare AOS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOS | QGEN |
|---|---|---|
| Founded | 1874 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 10.2B |
| IPO Year | 1994 | 1998 |
| Metric | AOS | QGEN |
|---|---|---|
| Price | $60.10 | $34.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $75.44 | $45.76 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | 2.26% | ★ 7.17% |
| EPS Growth | ★ 6.06 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $3,830,200,000.00 | N/A |
| Revenue This Year | $4.51 | $8.18 |
| Revenue Next Year | $3.80 | $5.71 |
| P/E Ratio | ★ $16.05 | $24.01 |
| Revenue Growth | ★ 0.32 | N/A |
| 52 Week Low | $59.83 | $33.17 |
| 52 Week High | $81.87 | $57.82 |
| Indicator | AOS | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 30.83 | 25.38 |
| Support Level | N/A | N/A |
| Resistance Level | $67.48 | $49.16 |
| Average True Range (ATR) | 1.91 | 0.95 |
| MACD | -0.24 | -0.58 |
| Stochastic Oscillator | 3.56 | 10.37 |
A.O. Smith Corp manufactures a broad lineup of water heaters, boilers, and water treatment products. The company has two reporting segments: North America (75% of sales) and the rest of the world (25% of sales). A.O. Smith is the manufacturer of water heaters in North America for the residential and commercial markets, with approximately 37% and 54% market share, respectively. Residential water heaters account for the majority of North American sales and are distributed equally through wholesale and retail channels. The majority of A.O. Smith's international revenue is from China, a market the company entered during the mid-1990s. However, the firm announced a strategic review of its China operations.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).